Table 1 Baseline characteristics
baseline characteristics | Intervention group (n = 13) | Control group (n = 12) |
|---|---|---|
Demographic data | ||
Age, yrs | 62 ± 3 | 54 ± 4 |
Gender, male/female | 12/1 | 11/1 |
BMI, kg/m2 | 25 ± 1 | 24 ± 1 |
Smoking history, pack-years | 39 ± 9 | 30 ± 7 |
Pulmonary function tests | ||
FEV1, % predicted | 85 ± 6 | 77 ± 8 |
FVC, % predicted | 102 ± 4 | 96 ± 8 |
FEV1/ FVC, % | 65 ± 4 | 62 ± 4 |
IC, % predicted | 90 ± 6 | 96 ± 8 |
MVV, % predicted | 91 ± 7 | 81 ± 9 |
COPD grade | ||
Pre-COPD, % | 3 (23.08) | 2 (16.67) |
GOLD Stage I, % | 7 (53.85) | 6 (50.00) |
GOLD Stage II, % | 1 (7.70) | 2 (16.67) |
GOLD Stage III, % | 2 (15.38) | 1 (8.33) |
GOLD Stage IV, % | 0 (0) | 1 (8.33) |
Treatment | ||
Inhaled corticosteroids | 6 (46.15) | 6 (50.00) |
Long-acting ß-agonists | 8 (61.54) | 9 (75.00) |
Long-acting muscarinic antagonists | 8 (61.54) | 10 (83.33) |
6MWT | ||
6MWD, m | 545 ± 22 | 525 ± 31 |
Initial heart rate, beats/min | 82 ± 3 | 88 ± 4 |
End heart rate, beats/min | 100 ± 6 | 113 ± 6 |
Initial SpO2, % | 96 ± 1 | 96 ± 0 |
Minimal SpO2, % | 93 ± 1 | 93 ± 0 |
End SpO2, % | 95 ± 1 | 95 ± 0 |
Initial Borg-Dyspnea | 0 (0–0.25) | 0 (0–0) |
End Borg-Dyspnea | 2 (0.75–3) | 1 (0.5–2) |
Initial Borg-Fatigue | 0 (0–0) | 0 (0–0) |
End Borg-Fatigue | 0.5 (0.5–2) | 0.75 (0.5–1) |
PETCO2 | 33 ± 1 | 36 ± 1 |
mMRC score | 1 (1–1) | 0.5 (0–1.75) |